Thalidomide
- Generic Name
- Thalidomide
- Brand Names
- Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C13H10N2O4
- CAS Number
- 50-35-1
- Unique Ingredient Identifier
- 4Z8R6ORS6L
- Background
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators li...
- Indication
Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
- Associated Conditions
- Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
- Associated Therapies
- -
Interferon Alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 90
- Registration Number
- NCT00027664
- Locations
- 🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom
🇬🇧Oxford Radcliffe Hospital, Oxford, England, United Kingdom
🇬🇧Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Registration Number
- NCT00052416
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Fletcher Allen Health Care - University Health Center Campus, Burlington, Vermont, United States
Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Herbert Irving Comprehensive Cancer Center
- Registration Number
- NCT00033709
- Locations
- 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States
Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 332
- Registration Number
- NCT00033254
- Locations
- 🇺🇸
Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, United States
Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT00047294
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes
- Conditions
- First Posted Date
- 2002-12-24
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 220
- Registration Number
- NCT00050843
- Locations
- 🇺🇸
Beaumont Cancer Center, Royal Oak, Michigan, United States
🇺🇸Texas Oncology PA-BMT Center, Dallas, Texas, United States
🇺🇸Northwest Medical Specialists, Arlington Heights, Illinois, United States
A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 17
- Registration Number
- NCT00001680
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 64
- Registration Number
- NCT00001446
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas
- First Posted Date
- 2002-10-23
- Last Posted Date
- 2011-10-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 7
- Registration Number
- NCT00047879
- Locations
- 🇺🇸
National Institutes of Health, Bethesda, Maryland, United States
Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2002-05-30
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00038246
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.